Sialix Moves into SDs Janssen Labs to Focus on Inflammatory Target
Summary
Sialix Moves into SD’s Janssen Labs to Focus on Inflammatory Target Xconomy San Diego — Experts in nutrition science have long fretted about the correlation between diets that are rich in certain foods—such as red meat and dairy products—with an increased risk of heart attacks, cancer, and other diseases associated with inflammation.Varki, who has been working in the area for more than a decade, has shown that Neu5Gc provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.Miralles, who also is a San Diego Xconomist, wrote recently that Janssen Labs is an example of a broader effort by big pharmaceutical companies to stimulate innovation in drug development.Behrens said, “It is truly no strings attached,” and that he feels free to initiate relationships with different pharmaceutical partners and to control the direction of Sialix products.To tackle these targets, Sialix is developing monoclonal antibodies to aggressively bind and destroy cells that express these non-human sialic acids and other cancer-specific glycans.